Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation

References

• GrimesDGordonJSnelgroveBCanadian guidelines on Parkinson’s diseaseCan J Neurol Sci201239S1S30
   PubMed Web of Science ®Google Scholar
• KaliaLVLangAEParkinson’s diseaseLancet201538689691225904081
   PubMed Web of Science ®Google Scholar
• ConnollyBSLangAEPharmacological treatment of Parkinson disease: a reviewJAMA20143111670168324756517
   PubMed Web of Science ®Google Scholar
• RichyFFPietriGMoranKASeniorEMakaroffLECompliance with pharmacotherapy and direct healthcare costs in patients with Parkinson’s disease: a retrospective claims database analysisAppl Health Econ Health Policy20131139540623649891
   PubMedGoogle Scholar
• PoulopoulosMWatersCCarbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s diseaseCore Evid2010511020694135
   PubMedGoogle Scholar
• StocchiFHsuAKhannaSComparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patientsParkinsonism Relat Disord2014201335134025306200
   PubMed Web of Science ®Google Scholar
• BrooksDJSagarHEntacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomized, placebo controlled, double blind, six month studyJ Neurol Neurosurg Psychiatry2003741071107912876237
   PubMed Web of Science ®Google Scholar
• Rodríguez-BlázquezCForjazMJLizánLPazSMartínez-MartínPEstimating the direct and indirect costs associated with Parkinson’s diseaseExpert Rev Pharmacoecon Outcomes Res20151588991126511768
   PubMed Web of Science ®Google Scholar
• FoxSHKatzenschlagerRLimSYThe Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s diseaseMov Disord201126S2S4122021173
   PubMed Web of Science ®Google Scholar
• FerreiraJJKatzenschlagerRBloemBRSummary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s diseaseEur J Neurol20132051523279439
   PubMed Web of Science ®Google Scholar
• HughesAJDanielSEKilfordLLeesAJAccuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 casesJ Neurol Neurosurg Psychiatry1992551811841564476
   PubMed Web of Science ®Google Scholar
• ReichmannHEmreMOptimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacaponeExpert Rev Neurother20121211913122288667
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGøtzschePCThe Cochrane collaboration’s tool for assessing risk of bias in randomized trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• HusereauDDrummondMPetrouSConsolidated Health Economic Evaluation Reporting Standards (CHEERS) statementValue Health201316e1e523538200
   PubMed Web of Science ®Google Scholar
• HigginsJPGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0Hoboken (NJ)Wiley2011
   Google Scholar
• SedgwickPStandard deviation or the standard error of the meanBMJ2015350h83125691433
   PubMed Web of Science ®Google Scholar
• FungVSHerawatiLWanYQuality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacaponeMov Disord200924253118846551
   PubMed Web of Science ®Google Scholar
• HauserRAPanissetMAbbruzzeseGDouble-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s diseaseMov Disord20092454155019058133
   PubMed Web of Science ®Google Scholar
• StocchiFRascolOKieburtzKInitiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD studyAnn Neurol201068182720582993
   PubMed Web of Science ®Google Scholar
• TolosaEHernándezBLinazasoroGEfficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trialJ Neural Transm (Vienna)201412135736624253234
   PubMed Web of Science ®Google Scholar
• LiJHeJJYiRWangHEWuJJA clinical study of levodopa/carbidopa combined with entacapone in Parkinson’s diseaseXian Dai Sheng Wu Yi Xue Jin Zhan201616504506
   Google Scholar
• No authors listedEntacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patientsAnn Neurol1997427477559392574
   PubMed Web of Science ®Google Scholar
• LewMFSomogyiMMcCagueKWelshMImmediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson’s disease with end-of dose wearing offInt J Neurosci201112160561321843110
   PubMed Web of Science ®Google Scholar
• FindleyLJLeesAApajasaloMPitkänenATurunenHCost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson’s disease patients with wearing-offCurr Med Res Opin2005211005101416004667
   PubMed Web of Science ®Google Scholar
• BhidayasiriRMartinez-MartinPClinical assessments in Parkinson’s disease: scales and monitoringInt Rev Neurobiol201713212918228554406
   PubMed Web of Science ®Google Scholar
• KuoppamäkiMVahteristoMEllménJKieburtzKPooled analysis of phase III with entacapone in Parkinson’s diseaseActa Neurol Scand201413023924725186800
   PubMed Web of Science ®Google Scholar
• LiJLouZLiuXSunYChenJEfficacy and safety of adjuvant treatment with entacapone in advanced Parkinson’s disease with motor fluctuation: a systematic meta-analysisEur Neurol20177814315328813703
   PubMed Web of Science ®Google Scholar
• Martinez-MartinPRodriguez-BlazquezCForjazMJKurtisMMImpact of pharmacotherapy on quality of life in patients with Parkinson’s diseaseCNS Drugs20152939741325968563
   PubMed Web of Science ®Google Scholar
• BrooksDJAgidYEggertKWidnerHØstergaardKHolopainenATreatment of end-of-dose wearing-off in Parkinson’s disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of tradition levodopa/DDCI treatmentEur Neurol20055319720215970632
   PubMed Web of Science ®Google Scholar
• KollerWGuarnieriMHubbleJRabinowiczALSilverDAn open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-offJ Neural Transm (Vienna)200511222123015503197
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in HealthCommon drug review: carbidopa, levodopa and entacapone2008 Available from: https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Stalevo_October-2008.pdfAccessed November 20, 2017
   Google Scholar
• NissinenHKuoppamäkiMLeinonenMSchapiraAHEarly versus delayed initiation of entacapone in levodopa-treated patients with Parkinson’s disease: a long-term, retrospective analysisEur J Neurol2009161305131119570145
   PubMed Web of Science ®Google Scholar
• ZhuoCZhuXJiangRComparison for efficacy and tolerability among ten drugs for treatment of Parkinson’s disease: a network meta-analysisSci Rep201784586528374775
   PubMed Web of Science ®Google Scholar
• Novartis [webpage on the Internet]A randomized, double-blind, parallel-group, multi-national study to compare the effect on quality of life of levodopa/carbidopa/entacapone with levodopa/carbidopa in patients with Parkinson’s disease with no or minimal non-disabling motor fluctuations2007 Available from: https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2366Accessed November 20, 2017
   Google Scholar
• HauserRALevodopa/carbidopa/entacapone (Stalevo)Neurology200462S64S7114718682
   PubMed Web of Science ®Google Scholar
• DeleaTEThomasSKHagiwaraMMancioneLAdherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson’s diseaseCurr Med Res Opin2010261543155220429819
   PubMed Web of Science ®Google Scholar